The U.S. Food and Drug Administration has approved Shionogi's Xocova (ensitrelvir), an oral antiviral, for postexposure ...
The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention landscape. Amid the approval, Noah Greenspan, DPT, PT, owner and founder of ...
Safety and tolerability of a novel monoclonal antibody cocktail for rabies post-exposure prophylaxis
Rabies is one of the most lethal viral zoonoses, particularly in low- and middle-income countries where access to post-exposure prophylaxis is limited. Conventional post-exposure prophylaxis relies on ...
Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 ...
FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results